Unidad de Enfermedades Infecciosas. Departamento de Medicina Interna, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana (IDIPHSA), Universidad Autónoma de Madrid, Joaquín Rodrigo 2, 2822, Majadahonda, Madrid, Spain.
Departamento de Inmunología, Hospital Universitario Puerta de Hierro, Joaquín Rodrigo 2, 2822, Majadahonda, Madrid, Spain.
Anaerobe. 2021 Dec;72:102475. doi: 10.1016/j.anaerobe.2021.102475. Epub 2021 Nov 6.
Determination of the humoral response to Clostridioides difficile (CD) toxins could be of great value in the management of patients with CD infection (CDI).
A prospective study was conducted on the clinical characteristics and humoral response in patients with CDI. Determination of ELISA IgG CD anti-toxin B (tgcBiomics, Germany) was performed. The following dilutions were planned for each patient, 1:100, 1: 200, 1: 400, 1: 800: 1: 1600. A significant concentration of antibody was considered to be present in each dilution if an optical density 0.2 units higher than the negative control of the technique was evident.
Eighty-five patients were included during the study period, November 2018-February 2020. The median age was 73 years (interquartile range: 62.5-85 years), with female predominance (45 patients, 52.9%). Thirty-nine patients (45.9%) had a severe infection. Seven patients (8.2%) had suffered an episode of CDI in the previous three months. Seventeen patients (20%) had one or more recurrent episodes during the three-month follow-up: No patient died during admission or required surgery for severe-complicated infection. The incidence of recurrence in patients with no antibody detected at 1:400 dilution was 25.4% (16 patients) while it was 4.3% (one patient) in patients with antibody present at that dilution (p = 0.03). Liver cirrhosis was associated with higher humoral response against CD.
Antibodies IgG CD anti-toxin B detection at a dilution of 1:400, using a B ELISA technique, effectively identified patients at increased risk of recurrence. This information could help assist in the management of patients.
对艰难梭菌(CD)毒素的体液反应的测定在艰难梭菌感染(CDI)患者的管理中可能具有重要价值。
对 CDI 患者的临床特征和体液反应进行了前瞻性研究。使用 ELISA IgG CD 抗毒素 B(tgcBiomics,德国)进行检测。为每位患者计划了以下稀释度,1:100、1:200、1:400、1:800、1:1600。如果技术的阴性对照高出 0.2 个单位,则认为每个稀释度存在明显浓度的抗体。
在研究期间,即 2018 年 11 月至 2020 年 2 月,共纳入 85 例患者。中位年龄为 73 岁(四分位距:62.5-85 岁),女性占优势(45 例,52.9%)。39 例(45.9%)患者感染严重。7 例(8.2%)患者在过去三个月内发生过一次 CDI 发作。17 例(20%)患者在三个月随访期间发生一次或多次复发:无患者在住院期间死亡或因严重合并感染需要手术。在未检测到 1:400 稀释度抗体的患者中,复发发生率为 25.4%(16 例),而在该稀释度存在抗体的患者中,复发发生率为 4.3%(1 例)(p=0.03)。肝硬化与对 CD 的更高体液反应相关。
使用 B ELISA 技术在 1:400 稀释度检测 IgG CD 抗毒素 B 可有效识别复发风险增加的患者。这些信息可以帮助辅助患者管理。